Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Autor:	Peters, Solange1, Ross Camidge, D.2, Shaw, Alice T.3, Gadgeel, Shirish4, Ahn, Jin S.5, Dong-Wan Kim6, Ou, Sai-Hong I.7, Pérol, Maurice8, Dziadziuszko, Rafal9, Rosell, Rafael10, Zeaiter, Ali11, Mitry, Emmanuel11, Golding, Sophie11, Balas, Bogdana11, Noe, Johannes11, Morcos, Peter N.12, Mok, Tony13 tony@clo.cuhk.edu.hk, Camidge, D Ross14 (AUTHOR), Kim, Dong-Wan14 (AUTHOR), ALEX Trial Investigators (CORPORATE AUTHOR)
Zdroj:	New England Journal of Medicine. 8/31/2017, Vol. 377 Issue 9, p829-838. 10p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu